http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012147739-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
filingDate | 2012-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2014-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2012147739-A |
titleOfInvention | ORAL COMPOSITIONS CONTAINING CYTIDINE ANALOGUES AND METHODS OF USE THEREOF |
abstract | 1. A pharmaceutical composition for oral administration containing a therapeutically effective amount of 5-azacytidine, wherein the composition releases 5-azacytidine substantially in the stomach after oral administration to a subject. A composition according to claim 1, which is an immediate release composition. A composition according to claim 1, which is not coated with an enteric coating. The composition of claim 1, which is a tablet. The composition of claim 1, which is a capsule. 6. A composition according to claim 1, which further comprises an excipient selected from mannitol, microcrystalline cellulose, crospovidone and magnesium stearate. The composition of claim 1, further comprising a penetration enhancing agent. The composition of claim 7, wherein the penetration enhancing agent is d-alpha-tocopheryl polyethylene glycol 1000 succinate. The composition of claim 8, wherein d-alpha-tocopheryl polyethylene glycol 1000 succinate is present in the composition in an amount of about 2% by weight relative to the total weight of the composition. A composition according to claim 1, which essentially does not contain a cytidine deaminase inhibitor. A composition according to claim 1, which essentially does not contain tetrahydrouridin. A composition according to claim 1, which further comprises an additional therapeutic agent. The composition of claim 1, wherein the amount of 5-azacytidine is at least about 40 mg. The composition of claim 1, wherein the amount of 5-azacytidine is at least about 400 mg. The composition of claim 1, wherein the amount of 5-azacytidine is at least about 1000 mg. The composition according to claim 1, which reaches the value of the area under the curve at least |
priorityDate | 2008-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.